Acorda's Parkinson's Drug Tozadenant May Not Survive Safety Setback
Executive Summary
The safety problems reported for tozadenant – including deaths – have not been reported for other A2a receptor inhibitors and the company sees them as "idiosyncratic," stirring doubts about a commercial future.
You may also be interested in...
Acorda Decides Tozadenant Isn’t Salvageable, Moves Primary Focus To Inbrija
Days after revealing seven cases of sepsis in trial participants receiving tozadenant – including five deaths – Acorda terminates development of the Phase III Parkinson’s candidate.
Acorda Investor Scopia Seeks Big Return From Sale Of The Company
Citing recent deals, hedge fund Scopia encouraged Acorda's board on Aug. 7 to pursue a sale, but the company believes its new strategy focused on Parkinson's disease is best for shareholders.
Keeping Track: US FDA Approves Sickle Cell Therapy Endari; Array Submits Binimetinib Again
The latest drug development news and highlights from our FDA Performance Tracker.